Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome from Non-Controlling InterestsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax RateTax Rate
Others
Ratios

Oramed Pharmaceuticals (ORMP) Income from Non-Controlling Interests (2021 - 2025)

Oramed Pharmaceuticals filings provide 5 years of Income from Non-Controlling Interests readings, the most recent being -$6000.0 for Q3 2025.

  • Quarterly Income from Non-Controlling Interests rose 73.91% to -$6000.0 in Q3 2025 from the year-ago period, while the trailing twelve-month figure was -$44000.0 through Dec 2025, down 2.33% year-over-year, with the annual reading at -$34000.0 for FY2025, 20.93% up from the prior year.
  • Income from Non-Controlling Interests hit -$6000.0 in Q3 2025 for Oramed Pharmaceuticals, up from -$28000.0 in the prior quarter.
  • Across five years, Income from Non-Controlling Interests topped out at $834000.0 in Q4 2023 and bottomed at -$751000.0 in Q3 2021.
  • Average Income from Non-Controlling Interests over 5 years is -$132533.3, with a median of -$62000.0 recorded in 2023.
  • The largest annual shift saw Income from Non-Controlling Interests skyrocketed 242.08% in 2023 before it plummeted 250.0% in 2025.
  • Oramed Pharmaceuticals' Income from Non-Controlling Interests stood at -$751000.0 in 2021, then grew by 21.84% to -$587000.0 in 2022, then skyrocketed by 242.08% to $834000.0 in 2023, then tumbled by 101.2% to -$10000.0 in 2024, then surged by 40.0% to -$6000.0 in 2025.
  • Per Business Quant, the three most recent readings for ORMP's Income from Non-Controlling Interests are -$6000.0 (Q3 2025), -$28000.0 (Q2 2025), and -$10000.0 (Q4 2024).